RISK MANAGEMENT: REGULATORY EXPECTATION, RISK PERCEPTION, AND ORGANIZATIONAL INTEGRATION - Risk Management Applications in Pharmaceutical and Biopharmaceutical Manufacturing - page 71

34. Breyer S. Breaking the vicious circle : toward effective risk regulation. Cambridge:
Harvard University; 1993.
35. Breyer S. Active Liberty. In: Interpreting our Democratic Constitution. New York:
Knopft; 2005.
36. Calabbresi, M., After Avandia: Does the FDA Have a Drug Problem, Time. Aug
12, 2010 Available at http://www.time.com/time/magazine/article/0,9171,2010181,00
.html, Accessed Dec 26 2011.
37. FDA Press Release, Justice Department takes action against McNeil-PPC Inc.
Charged with manufacturing and distributing OTC drugs in violation of federal
law, Available at http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements
/ucm246685.htm. Accessed Dec 26 2011.
38. Wilkinson, A., S. Elahi, and E. Eidinow (2003) Section 2 Background and dynamics
of the scenarios.Journal of Risk Research. Vol 6. No . 4-6:365-401.
39. Commission of the European Communities. Communication from the Commission
on the precautionary principle. Brussels 2000. Available at ec.europa.eu/dgs/health
_consumer/library/pub/pub07_en.pdf. Accessed 2011 Dec 26.
40. Commission of the European Communities. Communication from the Commission
on the precautionary principle. Brussels 200015-16.
41. ISO 14971 Medical Devices—Application of Risk Management to Medical Devices,
International Organization for Standardization 2007, p. v.
42. MHRA Good Manufacturing Practice (GMP)—Quality Risk Management:
Frequently Asked Questions Available at: http://www.mhra.gov.uk/Howweregulate/
Medicines/Inspectionandstandards/GoodManufacturingPractice/FAQ/QualityRisk
Management/index.htm. Accessed Dec 26 2011.